| چکیده انگلیسی مقاله |
Glioblastoma (GBM) is the most common and aggressive primary malignant brain tumor with poor prognosis and high potential of dispersion to other brain tissues in adult. Effective and modern choices of treatment including chemotherapy with alkylating agents marginally extend survival of GBM. However, alkylating agents can lead to highly harmful mismatch during DNA replication causing apoptosis and cell death. Accordingly, O6-Methylguanine-DNA methyltransferase (MGMT) removes alkyl adducts, thereby causing resistance to alkylating drugs. Single-Nucleotide Polymorphisms (SNPs) in MGMT promoter region may play a role in the regulation of MGMT expression and prediction of glioma development risk. In order to evaluate the clinical significance of rs1625649 SNP in the MGMT promoter region of glioblastoma, genomic DNA from a series of 54 patients with GBM and 50 healthy individuals in Iranian population were collected for tetra ARMS PCR amplification. None of the "A" or "C" alleles were associated with tumor occurrence, the "AA" genotype was more frequent in healthy subjects, and the "AC" genotype was 4.6 times more common in patients with GBM. The longest survival time was observed in the "CC" genotype; however, this difference was not statistically significant. On the other hand, homozygous rs1625649 (AA genotype) was significantly associated with a better survival than the cases with heterozygous rs1625649 (CA genotype) or wild type rs1625649 (CC genotype), predicting better response to temozolomide-based chemotherapy. |
| نویسندگان مقاله |
| Reyhaneh Safaei
Department of Pathology, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran
| Hanieh Mojtahedi
Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran
| Sara Hanaei
Department of Neurosurgery, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran
| Azadehsadat Razavi
Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran
| Marzie Esmaeili
Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran
| Maryam Sadr
Molecular Immunology Research Center, Tehran University of Medical Sciences, Tehran, Iran
| Arezou Rezaei
Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran
| Maryam Edalatfar
Department of Neurosurgery, lmam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| Hamidreza Khayat Kashani
Department of Neurosurgery, lmam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| Mohsen Sadeghi-Naini
Department of Neurosurgery, Lorestan University of Medical Sciences, KhorramAbad, Iran
| Farzaneh Darbeheshti
Department of Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
| Jaber Gharehdaghi
Legal Medicine Research Center, Legal Medicine Organization, Tehran, Iran
| Mehdi Forouzesh
Legal Medicine Research Center, Legal Medicine Organization, Tehran, Iran
| Abdolali Ebrahimi
Department of Pathology, lmam Hossein Hospital, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| Nima Rezaei
|